Steven M. Johnson

Steven M. Johnson

Auto-generated profile, based on publicly available information

Steven M. Johnson

Indiana University School of Medicine

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SASanofar Abdeen
Sanofar Abdeen
NSNilshad Salim
Nilshad Salim
NMNajiba Mammadova
Najiba Mammadova
CSCorey M. Summers
Corey M. Summers
RFRochelle Frankson
Rochelle Frankson
SJSteven M. Johnson
Steven M. Johnson

30 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SASanofar Abdeen
Sanofar Abdeen
TKTrent Kunkle
Trent Kunkle
NSNilshad Salim
Nilshad Salim
RARay Anne-Marie
Ray Anne-Marie
NMNajiba Mammadova
Najiba Mammadova
SJSteven M. Johnson
Steven M. Johnson

1 November 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SASanofar Abdeen
Sanofar Abdeen
NSNilshad Salim
Nilshad Salim
NMNajiba Mammadova
Najiba Mammadova
CSCorey M. Summers
Corey M. Summers
KGKaren Goldsmith-Pestana
Karen Goldsmith-Pestana
SJSteven M. Johnson
Steven M. Johnson

4 November 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKTrent Kunkle
Trent Kunkle
SASanofar Abdeen
Sanofar Abdeen
NSNilshad Salim
Nilshad Salim
RARay Anne-Marie
Ray Anne-Marie
MSMckayla Stevens
Mckayla Stevens
SJSteven M. Johnson
Steven M. Johnson

1 April 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CWChun-Xiang Wu
Chun-Xiang Wu
JLJingling Liao
Jingling Liao
YPYangshin Park
Yangshin Park
XRXylena Reed
Xylena Reed
VEVictoria A. Engel
Victoria A. Engel
QHQuyen Q. Hoang
Quyen Q. Hoang
Mutation in Leucine Rich Repeat Kinase 2 (LRRK2) is a common cause of familial Parkinson's disease (PD). Recently, we showed that a disease-associated mutation R1441H rendered the GTPase domain of LRRK2 catalytically less active and thereby trapping it in a more persistently "on" conformation. However, the mechanism involved and characteristics of this "on" conformation remained unknown. Here, we report that the ROC domain of LRRK2 exists in a dynamic dimer-monomer equilibrium that is oppositely driven by GDP and GTP binding. We also observed that the PD-associated mutations at residue 1441 impair this dynamic and shift the conformation of ROC to a GTP-bound-like monomeric conformation. Moreover, we show that residue Arg-1441 is critical for regulating the conformational dynamics of ROC. In summary, our results reveal that the PD-associated substitutions at Arg-1441 of LRRK2 alter monomer-dimer dynamics and thereby trap its GTPase domain in an activated state.

1 May 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
MSMckayla Stevens
Mckayla Stevens
SASanofar Abdeen
Sanofar Abdeen
NSNilshad Salim
Nilshad Salim
RARay Anne-Marie
Ray Anne-Marie
AWAlex Washburn
Alex Washburn
SJSteven M. Johnson
Steven M. Johnson
All living organisms contain a unique class of molecular chaperones called 60 kDa heat shock proteins (HSP60 - also known as GroEL in bacteria). While some organisms contain more than one HSP60 or GroEL isoform, at least one isoform has always proven to be essential. Because of this, we have been investigating targeting HSP60 and GroEL chaperonin systems as an antibiotic strategy. Our initial studies focused on applying this antibiotic strategy for treating African sleeping sickness (caused by Trypanosoma brucei parasites) and drug-resistant bacterial infections (in particular Methicillin-resistant Staphylococcus aureus - MRSA). Intriguingly, during our studies we found that three known antibiotics - suramin, closantel, and rafoxanide - were potent inhibitors of bacterial GroEL and human HSP60 chaperonin systems. These findings prompted us to explore what other approved drugs, natural products, and known bioactive molecules might also inhibit HSP60 and GroEL chaperonin systems. Initial high-throughput screening of 3680 approved drugs, natural products, and known bioactives identified 161 hit inhibitors of the Escherichia coli GroEL chaperonin system (4.3% hit rate). From a purchased subset of 60 hits, 29 compounds (48%) re-confirmed as selective GroEL inhibitors in our assays, all of which were nearly equipotent against human HSP60. These findings illuminate the notion that targeting chaperonin systems might be a more common occurrence than we previously appreciated. Future studies are needed to determine if the in vivo modes of action of these approved drugs, natural products, and known bioactive molecules are related to GroEL and HSP60 inhibition.